A new antibody shot that protects babies against RSV infection could be struggling to gain traction, researchers report.

The American College of Obstetricians and Gynecologists (ACOG) plans to develop and release recommendations on maternal ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...

Vaccines do much more than prevent specific diseases — their side benefits save children's lives around the world ...